The Full Comparison Table

Sorted by our overall score. “All-in” means what you would realistically pay each month once membership and medication are both counted — where a provider bills medication separately through insurance or a pharmacy, we say so rather than inventing a number.

Our previously reviewed platforms — CoreAge RX, LifeMD, MultiMedRx, FuturHealth, Zeus Health, and Ascend Medical — have their own full reviews.

How We Scored These Providers

Every provider was scored on the same five criteria, each out of 10. The overall score is a weighted blend, with value and transparency carrying the most weight because those are the two things readers consistently get burned on.

Value (weighted heaviest)

Not “cheapest,” but what you get for the total price once membership and medication are both counted. A $199/month all-in program scores better than a $99/month medication price with a $99/month membership attached, because the second one is more expensive and harder to see.

Transparency

Does the provider publish its prices where you can find them before handing over payment details? Does it name the pharmacy? Does it say plainly whether medication is included? A provider that hides pricing in a legal document scores lower than one with a clean pricing page, even at the same price.

Medical oversight

Who is actually prescribing, and how deep does the clinical relationship go? Obesity medicine specialists and menopause-trained physicians score higher than asynchronous questionnaire review. Manufacturer pharmacies score lower here by design — they sell medication and leave clinical care to your own prescriber.

Support

Coaching, messaging access, follow-up visits, and what happens when side effects hit during titration. Unlimited visits score well. A prescription and a shipping notification score poorly.

What we did not do

• ▪We did not sign up for these services or test the onboarding ourselves, and we do not claim to have.
• ▪We did not accept payment from any provider in exchange for placement or a score.
• ▪We did not include user-review star ratings from third-party sites, which are easily manipulated in this industry.
• ▪We did not estimate prices. Where a provider does not publish one, the review says so.

Eight Patterns Worth Knowing Before You Choose

1. Brand-name is no longer automatically the expensive option

This is the biggest change in the market. NovoCare Pharmacy publishes the Wegovy pill at $149/month and the pen at $199/month. LillyDirect publishes Zepbound self-pay from $299/month at the starter dose. Amazon One Medical publishes oral GLP-1s from $149/month cash-pay or as low as $25/month with insurance. Two years ago, compounded medication was the only affordable route. That is no longer true, and anyone shopping on price alone should check the manufacturer pharmacies before assuming otherwise.

2. The headline price is usually half the bill

Mochi, Eden, Ivím, Alloy, Lemonaid, and Found all separate a membership fee from a medication fee. Eden in particular is widely quoted at “$99/month” in roundups that predate the membership fee reportedly added in 2026. Add both numbers before comparing anything.

3. Your price goes up as your dose goes up — unless it doesn't

LillyDirect Zepbound runs $299 at the starter dose and $699 at maintenance. That is a real $4,800 a year difference that a starter-dose quote completely hides. Mochi, Brello, Found, and TrimRx publish flat pricing across doses, which is worth a premium if you expect to titrate up.

4. Quarterly and annual billing hides the commitment

Brello advertises “$133/month” but charges $399 up front every 11 weeks. Noom bills quarterly. Sesame's cheapest rate needs an annual subscription. None of this is dishonest, but the advertised monthly figure is not what hits your card.

5. Free is a real option for more people than you would think

Five providers in this table cost eligible members nothing, because an employer or health plan pays: Teladoc (connected scale and a 25-week curriculum), Omada (a GLP-1 companion program), Twin Health (built around eventually stopping GLP-1s), Vida, and Wondr. 9amHealth runs an employer channel too, alongside a $149/month individual plan.

Some plans go further than offering these — Massachusetts made Vida's program a requirement for GLP-1 weight-loss coverage for eligible members from January 1, 2026. And if you are on Medicare, the Medicare GLP-1 Bridge program caps eligible GLP-1s at $50/month. Check all of this before paying anyone.

6. Almost nobody tells you which pharmacy makes your medication

Read our compounded reviews and one sentence keeps recurring: “does not publicly name an exclusive pharmacy.” That is the norm, not an oversight. You are buying a product that has not been through FDA review, and most companies will not tell you who made it.

Five providers break the pattern, and one does it better than the rest. Sunlight names six — Belmar, Strive, Epiq Scripts, Casa Pharma Rx, The Pharmacy Hub and Foothills — along with the medical groups its clinicians work through. Ondra Health publicly names all five of its compounding pharmacy partners and issued a press release about the disclosure. Embody lists its four — RedRock, Health Warehouse, Precision Compounding and Triad Rx — with addresses and phone numbers in its footer. Trimi also names its pharmacy. Fifty 410 discloses the facility type — FDA-registered 503A and 503B compounding pharmacies — which is a step short of naming, but more than most.

If you are going to take a compounded medication, being able to look up who made it is worth something. Ask the question of any provider you are considering, and treat a non-answer as information.

7. Compounded copies of the new oral pills have arrived

In February 2026, Hims & Hers launched a compounded oral semaglutide pill at $49 for the first month and $99 afterwards — a copy of the Wegovy pill Novo Nordisk sells at $149 — and pulled it within days. Novo sued for patent infringement on 9 February 2026, seeking an injunction running to the patent's expiry in December 2031.

It resolved quickly, and the settlement is the more important development. On 9 March 2026 Novo dismissed the suit, Hims gained expanded access to sell FDA-approved semaglutide, and Hims agreed to stop advertising compounded GLP-1 drugs altogether — exiting compounded semaglutide for new patients. Read alongside the February warning letters, the direction is consistent: the largest players are being moved off compounded GLP-1s and onto approved products, and the price gap that used to justify compounding is now measured in tens of dollars rather than hundreds.

8. The FDA has started naming names

In February 2026 the FDA issued warning letters to 30 telehealth companies over false or misleading claims about compounded GLP-1s. Four providers in this table are among them. MEDVi received a letter dated 20 February 2026 in which the FDA objected to claims that its compounded products contained the “same active ingredient as Wegovy® and Ozempic®” on the basis that this implied FDA approval, and found that pictured labels bearing the MEDVi name suggested it was the compounder when it was not. SkinnyRx received a letter on the same date after the FDA reviewed its site and concluded its claims were false or misleading, rendering the products misbranded. And Strut Health received one too, where the FDA found that product labels bearing the Strut name suggested it was the compounder “when in fact it is not”. The fourth is Ivím Health, which scores highly here on clinical access: the FDA reviewed its website in December 2025 and concluded on 20 February 2026 that its compounded semaglutide and tirzepatide were misbranded under sections 502(a) and 502(bb). Ivím's pricing page now carries a fuller compounding disclosure than most of its competitors do, which reads like a response.

These are findings about advertising rather than about the medication in the vial, and none of these companies stopped trading. But they are the clearest signal yet of where the regulator is heading, and they sit alongside the FDA's May 2026 proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list. If you are choosing a compounded provider, the FDA warning letter database is free, searchable, and worth two minutes of your time before you hand over payment details.

Frequently Asked Questions

Where to Go Next

• ▪Best online GLP-1 providers — our picks by category rather than a single ranking
• ▪What GLP-1s actually cost in 2026 — every pricing route, including manufacturer self-pay
• ▪Brand-name vs compounded — what the regulatory changes mean for you
• ▪Insurance coverage guide — including the Medicare GLP-1 Bridge program